Gene expression profiling reveals potential key pathways involved in pyrazinamide-mediated hepatotoxicity in Wistar rats

Journal of Applied Toxicology

Volumn 33, Issue 8, 2013, Pages 807-819

  Zhang, Yun ^a   Jiang, Zhenzhou ^a   Su, Yijing ^a   Chen, Mi ^a   Li, Fu ^a   Liu, Li ^b   Sun, Lixin ^a   Wang, Yun ^a   Zhang, Shuang ^a   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b CHANGZHOU UNIVERSITY   (China)

Author keywords

Gene expression; Hepatotoxicity; Microarray analysis; Pathway analysis; Pyrazinamide

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CYCLIN DEPENDENT KINASE 4; CYTOCHROME P450 2B1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; HEME OXYGENASE 1; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PYRAZINAMIDE; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE CONTROL; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; IN VIVO STUDY; LIPID METABOLISM; LIVER INJURY; LIVER TOXICITY; LIVER WEIGHT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UNINDEXED SEQUENCE;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUTATHIONE; LIVER; MALE; MALONDIALDEHYDE; MICROARRAY ANALYSIS; OXIDATIVE STRESS; PYRAZINAMIDE; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SEX FACTORS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; SUPEROXIDE DISMUTASE;

RATTUS; RATTUS NORVEGICUS;

EID: 84879498016     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2736     Document Type: Article

References (54)

1. Ahn HS, Jeon TI, Lee JY, Hwang SG, Lim Y, Park DK. 2002. Antioxidative activity of persimmon and grape seed extract: in vitro and in vivo. Nutr. Res. 22: 1265-1273.
2. Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H. 2004. Ligand-induced expression of peroxisome proliferator-activated receptor α and activation of fatty acid oxidation enzymes in fatty liver. Eur. J. Clin. Invest. 34: 429-435.
3. American Thoracic Society/CDC. 2001. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. Morbid. Mortal. Wkly Rep. 50: 733-735.
4. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. 2009. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 10: 1467-1487.
5. Attri S, Rana S, Vaiphei K, Sodhi C, Katyal R, Goel R, Nain C, Singh K. 2000. Isoniazid- and rifampicin-induced oxidative hepatic injury-protection by N-acetylcysteine. Hum. Exp. Toxicol. 19: 517-522.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
7. Chang KC, Leung CC, Yew WW, Lau TY, Tam CM. 2008. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am. J. Respir. Crit. Care. Med. 177: 1391-1396.
8. Despres JP, Lemieux I, Robins SJ. 2004. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 64: 2177-2198.
9. Døssing M, Wilcke J, Askgaard D, Nybo B. 1996. Liver injury during antituberculosis treatment: an 11-year study. Tuber. Lung Dis. 77: 335-340.
10. Duplus E, Glorian M, Forest C. 2000. Fatty acid regulation of gene transcription. J. Biol. Chem. 275: 30749-30752.
11. Ellard GA HR. 1976. Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide. Tubercle 57: 97-103.
12. Global Alliance for TB Drug Development. 2008. Pyrazinamide. Tuberculosis 88: 141-144.
13. Gochfeld M. 2007. Framework for gender differences in human and animal toxicology. Environ. Res. 104: 4-21.
14. Gonzalez FJ. 2005. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res. Fund. Mol. Med. 569: 101-110.
15. Guo L, Shi Q, Dial S, Xia Q, Mei N, Li Q, Chan PC, Fu P. 2010. Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. Food. Chem. Toxicol. 48: 686-696.
16. Gupta P, Roy V, Sethi GR, Mishra TK. 2008. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br. J. Clin. Pharmacol. 65: 423-427.
17. Heijne WHM, Jonker D, Stierum RH, Ommen B, Groten JP. 2005. Toxicogenomic analysis of gene expression changes in rat liver after a 28-day oral benzene exposure. Mutat. Res. Fund. Mol. Med. 575: 85-101.
18. Honkakoski P, Sueyoshi T, Negishi M. 2003. Drug-activated nuclear receptors CAR and PXR. Ann. Med. 35: 172-182.
19. Inal ME, Kanbak G, Sunal E. 2001. Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin. Chim. Acta 305: 75-80.
20. Jasmer RM, Daley CL. 2003. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am. J. Respir. Crit. Care Med. 167: 809-810.
21. Kadiri S, Ajayi SO. 2000. Variability in the relationship between serum creatinine and creatinine clearance in hypertensives and normotensives with normal renal function. Afr. J. Med. Sci. 29: 93-96.
22. Keshava C, Divi RL, Einem TL, Richardson DL, Leonard SL, Keshava N, Poirier MC, Weston A. 2009. Chlorophyllin significantly reduces benzo [a] pyrene [BP]-DNA adduct formation and alters Cytochrome P450 1A1 and 1B1 expression and EROD activity in normal human mammary epithelial cells (NHMECs). Environ. Mol. Mutagen. 50: 134-144.
23. Kim H, Kwon Y, Rho S, Hahm Y. 1999. The role of fatty acid binding protein in the fatty liver induced by alcohol or high cholesterol diet in rats. Kor. J. Nutr. 32: 628-636.
24. Kim HK, Kim DS, Cho HY. 2007. Protective effects of Platycodi radix on alcohol-induced fatty liver. Biosci. Biotechnol. Biochem. 71: 1550-1552.
25. Klaunig J, Babich M, Baetcke K, Cook J, Corton J, David R. 2003. PPAR alpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33: 655-780.
26. Knobel B, Buyanowsky G, Dan M, Zaidel L. 1997. Pyrazinamide-induced granulomatous hepatitis. J. Clin. Gastroenterol. 24: 264-266.
27. Kovalenko V, Bondarenko L, Byshovetz T, Shayakhmetova G, Voronina A, Voloshina O, Saprykina N. 2006. Pyrazinamide and disulfiram effects on male rat's reproductive function. Toxicol. Lett. 164: S303-S304.
28. Kovalenko V, Bagnyukova T, Sergienko O, Bondarenko L, Shayakhmetova G, Matvienko A, Pogribny I. 2007. Epigenetic changes in the rat livers induced by pyrazinamide treatment. Toxicol. Appl. Pharmacol. 225: 293-299.
29. Lee MH, Kim JW, Kim JH, Kang KS, Kong G, Lee MO. 2011. Gene expression profiling of murine hepatic steatosis; induced by tamoxifen. Toxicol. Lett. 199: 416-424.
30. Li X, Ma Y, Liu X. 2007. Effect of the Lycium barbarum polysaccharides on age-related oxidative stress in aged mice. J. Ethnopharmacol. 111: 504-511.
31. Liu L, Jiang Z, Liu J, Huang X, Wang T, Liu J, Zhang Y, Zhou Z, Guo J, Yang L, Chen Y, Zhang L. 2010. Sex differences in subacute toxicity and hepatic microsomal metabolism of triptolide in rats. Toxicology 271: 57-63.
32. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25: 402-408.
33. Maciel ELN, Guidoni LM, Favero JL, Hadad DJ, Molino LP, Jonhson JL, Dietze R. 2010. Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian National Ministry of Health. J. Bras. Pneumol. 36: 232-238.
34. Maffei Facino R, Carini M. 1980. The inhibitory effect of pyrazinamide on microsomal monooxygenase activities is related to the binding to reduced cytochrome P-450. Pharmacol. Res. Commun. 12: 523-537.
35. McGarry JD, Brown NF. 1997. The mitochondrial carnitine palmitoyltransferase system from concept to molecular analysis. Eur. J. Biochem. 244: 1-14.
36. Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. 2004. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-α (PPARα)-regulated genes and is ameliorated by PPARα activation. J. Pharmacol. Exp. Ther. 310: 417-424.
37. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. 2004. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J. Pharmacol. Sci. 96: 293-300.
38. Niwa T, Shiraga T, Takagi A. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28: 1805-1808.
39. Rajaraman G, Wang G, Yan J, Jiang P, Gong Y, Burczynski F. 2007. Role of cytosolic liver fatty acid binding protein in hepatocellular oxidative stress: effect of dexamethasone and clofibrate treatment. Mol. Cell. Biochem. 295: 27-34.
40. Rao MS, Reddy JK. 2001. Peroxisomal beta-oxidation and steatohepatitis. Semin. Liver. Dis. 21: 43-55.
41. Sellamuthu R, Umbright C, Roberts JR, Chapman R, Young SH, Richardson D, Leonard H, McKinney W, Chen B, Frazer D. 2011. Blood gene expression profiling detects silica exposure and toxicity. Toxicol. Sci. 122: 253-264.
42. Shayakhmetova G, Bondarenko L, Saprykina N, Kovalenko V. 2006. Dose depending pyrazinamide effects on peroxidation processes and lipid contents in rats. Toxicol. Lett. 164: S72-S72.
43. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry 3rd C, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333: 1630-1632.
44. Slivka II, Klimniuk E, Tabachuk O. 1989. Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin. Probl. Tuberk. 4: 39-42.
45. Sun G, Thai SF, Tully DB, Lambert GR, Goetz AK, Wolf DC, Dix DJ, Nesnow S. 2005. Propiconazole-induced cytochrome P450 gene expression and enzymatic activities in rat and mouse liver. Toxicol. Lett. 155: 277-287.
46. Tostmann A, Aarnoutse RE, Peters WHM, Richard PNR, Boeree MJ. 2010. Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells. Drug. Chem. Toxicol. 33: 325-328.
47. Wang G, Gong Y, Anderson J, Sun D, Minuk G, Roberts MS, Burczynski FJ. 2005. Antioxidative function of l-FABP in l-FABP stably transfected Chang liver cells. Hepatology 42: 871-879.
48. Wang G, Shen H, Rajaraman G, Roberts MS, Gong Y, Jiang P, Burczynski F. 2007. Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. Eur. J. Pharmacol. 560: 61-68.
49. Wang T, Yu H, Wang W, Pan Y, He L, Wang Z. 2010. Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in chinese tuberculosis patients. J. Int. Med. Res. 38: 977-986.
50. Willson TM, Kliewer SA. 2002. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1: 259-266.
51. Wu B, Zhang Y, Zhao D, Zhang X, Kong Z, Cheng S. 2009. Gene expression profiles in liver of mouse after chronic exposure to drinking water. J. Appl. Toxicol. 29: 569-577.
52. Wyde ME, Bartolucci E, Ueda A, Zhang H, Yan B, Negishi M, You L. 2003. The environmental pollutant 1, 1-dichloro-2, 2-bis(p-chlorophenyl) ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Mol. Pharmacol. 64: 474-481.
53. Younossian A, Rochat T, Ketterer J, Wacker J, Janssens J. 2005. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur. Respir. J. 26: 462-464.
54. Zhang Q, Li N, Zhou G, Lu X, Xu Z, Li Z. 2003. In vivo antioxidant activity of polysaccharide fraction from Porphyra haitanesis (Rhodephyta) in aging mice. Pharmacol. Res. 48: 151-155.